Biomarin Pharmaceutical
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
Phase 2
Completed
- Conditions
- Endothelial Dysfunction
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT00532844
Sapropterin Expanded Access Program
- Conditions
- Phenylketonuria
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT00484991
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT00445978
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
Phase 2
Completed
- Conditions
- Intermittent Claudication
- Interventions
- Other: Placebo
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 190
- Registration Number
- NCT00403494
Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency
Phase 2
Completed
- Conditions
- Tetrahydrobiopterin DeficienciesHyperphenylalaninemia, Non-Phenylketonuric
- Interventions
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT00355264
Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
Phase 3
Completed
- Conditions
- Phenylketonuria
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 111
- Registration Number
- NCT00332189
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
Phase 2
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 84
- Registration Number
- NCT00325962
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Phase 4
Completed
- Conditions
- Mucopolysaccharidosis VIMaroteaux-Lamy Syndrome
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 4
- Registration Number
- NCT00299000
- Locations
- 🇵🇹
Hospital PediAtrico de Coimbra, Coimbra, Portugal
🇺🇸Children's Hospital Oakland, Oakland, California, United States
🇫🇷Hospital Femme Mere Enfant Centre, Lyon, France
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
Phase 3
Completed
- Conditions
- Phenylketonurias
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 45
- Registration Number
- NCT00272792
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Phase 3
Completed
- Conditions
- Phenylketonurias
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT00225615
© Copyright 2025. All Rights Reserved by MedPath